Effect of Flexible Catheter Materials on Catheter Angle and Blood Vessel Irritation

Not Applicable

Recruiting

• Conditions: Healthy; Intravenous Catheterization; Oedema; Thrombosis

• Registration Number: NCT06927141
• Lead Sponsor: Griffith University

Brief Summary

Peripheral intravenous catheters (PIVCs; commonly known as "cannulas") are very small tubes made out of rubber-like materials which are inserted into patients' arms using a needle to allow easy access to veins. They are the most commonly-used medical devices in the world, with almost 10 million placed each year in Australia alone. Approximately 40% (almost 4 million) of these devices stop working (i.e. fail) prior to completion of therapy.

The main goal of this study is to learn if softer, more flexible PIVC tip materials reduce the angle of the catheter tip on the vein surface compared to less flexible materials. Reducing the angle of the tip is believed to reduce rubbing on the inner vein surface and causing irritation, extending the life of the catheter. Other goals of this study are to learn if softer materials affect: volume of oedema (i.e. fluid leakage around the vein); time until catheter failure; clot volume in the vein; changes in vein size in response to catheter insertion; adverse event rates (i.e. changes in rates of specific, reportable symptoms); and determining if certain catheters are better for some people than others. This study is recruiting participants of all genders aged 18 - 75 years old who:

* Are not pregnant

* Have a Body Mass Index (BMI) between 18.5 - 35 kg/m2

* Have a current Australian Medicare card

* Do not have a history of chronic/infectious disease or clotting disorders

* Do not have a history of recreational drug use or alcohol abuse within the past 2 years

Participants will:

* Spend two hours in the clinic for screening blood collection, medical questionnaire and ultrasound imaging of veins

* Have one more flexible catheter and one less flexible catheter placed in opposite arms (i.e. participants will have a total of two catheters placed) which will remain in place either (i) until they fail or (ii) for 72 hours, whichever is earlier

* Spend eight hours per day in the clinic on the day the catheters are placed and the two days following for observation and ultrasound imaging

* Spend four hours in the clinic on the third day following placement of the catheters for observation, ultrasound imaging and catheter removal

* Spend one hour in the clinic 24-96 hours after catheter removal for a follow-up assessment and questionnaire

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-27
• Status Verified: 2025-04
• Study Start: 2025-04
• Study First Submitted QC: 2025-04-13
• Last Update Submitted: 2025-04-13
• Study First Posted: 2025-04-15
• Last Update Posted: 2025-04-15
• Primary Completion: 2025-10
• Study Completion: 2025-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Adult aged 18-75 years.
• Not pregnant at time of recruitment and within 48 hrs of Day 1 procedures (self-reported)
• Normal haematology results as per reference range determined by the laboratory.
• Normal coagulation results as per reference range determined by the laboratory.
• Target cephalic veins readily cannulatable (i.e., > 2 mm)
• Able and willing to provide verbal and written consent
• Must be an Australian citizen with current Medicare card

Exclusion Criteria

• History of pro coagulative state / condition (e.g., previous deep vein thrombosis)
• Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and aspirin will be documented however are not exclusionary.
• Haemophilia or any current or history of bleeding disorder or tendency
• Presence or report of current blood borne disease/infection (e.g., hepatitis, HIV, leukemia, lymphoma)
• History of difficult vascular access
• Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin adhesives
• BMI < 18.5 kg/m2 or ≥ 35 kg/m2
• Positive results for the urine drug screen at screening or check-in (including opiates, methadone, cocaine, amphetamines)
• History or presence of alcoholism (self-reported) or drug abuse within the past 2 years
• A current or previous medical, physical, mental / cognitive disorder or anatomical conditions that, in the opinion of the chief or sub-investigator, would place the patient at risk, would make them unable to perform study procedures or has the potential to confound interpretation of the study results. (e.g., musculo-skeletal injury, chronic back pain)
• Employed by Terumo, Becton Dickinson, Teleflex Medical, ICUMedical or BBraun (conflict of interest)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Catheter Angle	Baseline (Day 1: morning)	Measured against inferior border of vein using vascular ultrasound (in degrees)

Secondary Outcome Measures

Name	Time	Method
Vein segment volume	Morning visit (AM) after catheter insertion through to catheter removal and/or 72 hours post-insertion (whichever is earlier)	Measured by vascular ultrasound (in mm cubed/microliters)
Adverse Events	Morning visit (AM) after catheter insertion through to follow-up visit (up to 7 days)	Identified by study team and/or nurses and reviewed by a medical practitioner (identified individually and aggregate of all adverse events; expressed as a count and percentage of catheters inserted).
Volume of interstitial oedema	Morning visit (AM) after catheter insertion through to final interventional visit (up to 4 days)	Measured using vascular ultrasound (in mm cubed/microliters)
Time to catheter failure	Morning visit (AM) after catheter insertion through to catheter removal and/or 72 hours post-insertion (whichever is earlier)	Measured separately for each PIVC (in hours), including differences between catheters and survival analysis.
Thrombus volume in vein	Morning visit (AM) after catheter insertion through to catheter removal and/or 72 hours post-insertion (whichever is earlier)	Measured using vascular ultrasound (in mm cubed/microliters)

Trial Locations

Locations (1)

Griffith University; 🇦🇺 Southport, Queensland, Australia